These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35092319)

  • 1. Letter to the editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
    Kumar A; Sharma P; Arora A
    Hepatology; 2022 Jul; 76(1):E3-E4. PubMed ID: 35092319
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
    Jindal A
    Hepatology; 2022 Aug; 76(2):E42. PubMed ID: 35306689
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
    Feng Y; Peng B; Li Y; Sun L; Sun Y
    Hepatology; 2023 May; 77(5):E103-E104. PubMed ID: 36645222
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis.
    Salman MA; Mikhail HMS; Nafea MA; Sultan AAEA; Elshafey HE; Tourky M; Awad A; Abouelregal TE; Ahmed RA; Ashoush O; AbdelAal AA; Shaaban HE; Atallah M; Yousef M; Salman AA
    Surg Endosc; 2021 Mar; 35(3):1269-1277. PubMed ID: 32152677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.
    Lassailly G; Caiazzo R; Ntandja-Wandji LC; Gnemmi V; Baud G; Verkindt H; Ningarhari M; Louvet A; Leteurtre E; Raverdy V; Dharancy S; Pattou F; Mathurin P
    Gastroenterology; 2020 Oct; 159(4):1290-1301.e5. PubMed ID: 32553765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease.
    Mills PJ; Caussy C; Loomba R
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):741-743. PubMed ID: 30954713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years.
    Kawanaka M; Nishino K; Morimoto Y; Ishii K; Tanikawa T; Urata N; Suehiro M; Sasai T; Haruma K; Kawamoto H
    Intern Med; 2021 May; 60(9):1397-1401. PubMed ID: 33281161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis.
    Are VS; Vuppalanchi R; Vilar-Gomez E; Chalasani N
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1292-1293.e3. PubMed ID: 32629127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease.
    Liguori A; Zoncapè M; Tsochatzis EA
    Rev Esp Enferm Dig; 2022 Apr; 114(4):191-194. PubMed ID: 35187942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
    Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
    J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation.
    Sourianarayanane A; Arikapudi S; McCullough AJ; Humar A
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):481-487. PubMed ID: 28253211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Steatohepatitis.
    Suzuki A; Diehl AM
    Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and natural history of non-alcoholic fatty liver disease.
    Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM
    Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.